Buffett InvestorsNZX
Back
BLT.NZ

Blis Technologies Share Price: A 1.5-Cent Probiotics Play With Real Revenue Growth

Blis Technologies Share Price Today

The Blis Technologies share price sits at about $0.015 NZD (NZX: BLT) in mid-June 2026, roughly flat over the past year. With a market cap near $19 million spread across more than 1.2 billion shares, Blis is a Dunedin-based biotechnology micro-cap that has built a genuine, if small, business around oral probiotics, and is actually growing.

Unlike many micro-caps at this price level, Blis has real customers, real revenue growth, and a path, however narrow, to scaled profitability.

What Blis Technologies Does

Blis Technologies develops and manufactures advanced probiotics for the mouth and throat. Its science is built on specific strains of beneficial bacteria that naturally occur in the oral cavity, marketed as BLIS K12, BLIS Q24, and BLIS M18. These ingredients go into lozenges, supplements, and increasingly into foods, sold both directly to consumers (B2C) and to other manufacturers who use them as ingredients (B2B).

This makes Blis a natural-health and ingredients business, sharing some DNA with larger NZ wellness names like [Comvita](/stocks/comvita), but at a far earlier and smaller stage and with a more scientific, strain-based moat.

Recent Performance: Solid Growth

Blis has been delivering steady top-line growth:

  • •Nine-month revenue to December 2025 of about $10.8 million, up roughly 17% year on year
  • •Growth led by B2B revenue up about 21%, with B2C up around 9%
  • •A revised growth partnership with Probi AB to advance oral probiotics for both humans and pets

Double-digit revenue growth, led by the higher-leverage B2B channel and supported by a global partner, is a genuinely encouraging trajectory for a company this size. The business is around breakeven, with only a token profit, so the focus is on whether growth can lift it to sustained profitability.

Key Metrics

  • •Share price: ~$0.015 NZD
  • •Market cap: ~$19 million NZD
  • •9-month revenue: ~$10.8 million (up ~17%)
  • •P/E ratio (trailing): ~30x (on a tiny profit)
  • •Net tangible assets: ~$0.009 per share
  • •Gross dividend yield: 0%

The high P/E reflects how small the current profit is, not overvaluation in the usual sense. For Blis, revenue growth and the move toward scale matter far more than this year's earnings multiple.

What to Watch

  • •B2B momentum and partnerships: The Probi relationship and B2B ingredient sales are the highest-leverage growth path. Watch for new contracts and food applications.
  • •Profitability: Blis hovers near breakeven. The key question is whether growing revenue translates into a meaningful, sustained profit.
  • •Regulatory clearances: Approvals to use its strains in foods (in various markets) expand the addressable market.
  • •Liquidity and dilution: As a micro-cap, watch the cash position and any capital needs.

The Bottom Line

Blis Technologies is a small but real biotech business with differentiated probiotic science, double-digit revenue growth, and a global partner. The bull case is a strain-based ingredients company scaling its B2B channel toward genuine profitability. The bear case is that it remains tiny, only marginally profitable, and reliant on partners and regulatory wins, with the dilution risk common to micro-caps. This is a speculative growth stock for investors who believe the oral-probiotics niche can scale, not a stock to value on current earnings.

For how we evaluate small, growing biotech businesses, see our [methodology](/methodology).

*Disclaimer: This article is for educational and informational purposes only. It does not constitute financial advice. Stock data may not be real-time. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.*